Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.
Enthera Pharmaceuticals, an Italy-based biotechnology developer focused on autoimmune conditions, today collected €28m ($32.8m) in a series A round co-led by pharmaceutical firm AbbVie’s corporate venturing arm AbbVie Ventures.
VC firm Sofinnova Partners co-led the round, which also included unnamed individuals coordinated by wealth management firm Banor SIM and by asset management firm Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners.
Founded in 2016, Enthera Pharmaceuticals is working on treatments that re-establish stem cell capabilities in the pancreas and gut to tackle autoimmune diseases.
The company emerged out of biotech accelerator BiovelocITA to commercialise research by co-founders Paolo Fiorina and Francesca D’Addio, respective associate professor and assistant professor in endocrinology at University of Milan.
The series A capital will allow Enthera to move its lead asset, a proposed treatment for type 1 diabetes and inflammatory bowel disease, into human trials. The money will also support…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
